|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2006-12-20
|
|
pubmed:abstractText |
Bronchiolitis obliterans syndrome (BOS) remains the major cause of long-term morbidity and mortality after lung transplantation, and new therapeutic measures are needed. We speculated that cilomilast might reduce mediators of airway inflammation and angiogenesis from the airway epithelium, supporting a potential value in the treatment of BOS. We used an ex vivo primary bronchial epithelial cell culture (PBEC) model to investigate this hypothesis. Increasing evidence suggests the epithelium is central in stimulating both inflammatory and proliferative responses in the airway.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/3',5'-Cyclic-AMP Phosphodiesterases,
http://linkedlifedata.com/resource/pubmed/chemical/Carboxylic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Cilomilast,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic Nucleotide...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclohexanecarboxylic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte-Macrophage...,
http://linkedlifedata.com/resource/pubmed/chemical/Inflammation Mediators,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-8,
http://linkedlifedata.com/resource/pubmed/chemical/Nitriles,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphodiesterase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/VEGFA protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1557-3117
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1436-40
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17178338-3',5'-Cyclic-AMP Phosphodiesterases,
pubmed-meshheading:17178338-Bronchi,
pubmed-meshheading:17178338-Carboxylic Acids,
pubmed-meshheading:17178338-Cells, Cultured,
pubmed-meshheading:17178338-Cyclic Nucleotide Phosphodiesterases, Type 4,
pubmed-meshheading:17178338-Cyclohexanecarboxylic Acids,
pubmed-meshheading:17178338-Dose-Response Relationship, Drug,
pubmed-meshheading:17178338-Epithelial Cells,
pubmed-meshheading:17178338-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:17178338-Humans,
pubmed-meshheading:17178338-Inflammation Mediators,
pubmed-meshheading:17178338-Interleukin-6,
pubmed-meshheading:17178338-Interleukin-8,
pubmed-meshheading:17178338-Lung Transplantation,
pubmed-meshheading:17178338-Nitriles,
pubmed-meshheading:17178338-Phosphodiesterase Inhibitors,
pubmed-meshheading:17178338-Vascular Endothelial Growth Factor A
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
The phosphodiesterase type IV inhibitor cilomilast decreases pro-inflammatory cytokine production from primary bronchial epithelial cells in lung transplantation patients.
|
|
pubmed:affiliation |
The Applied Immunobiology and Transplantation Research Group Institute of Cellular Medicine, Newcastle-upon-Tyne, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
